 JanOne Inc. NASDAQ:JAN appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will chair the Companys scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD. Dr. Kevil is considered a foremost expert in the development and analysis of various small molecules, biologics, disease indications, pharmaceutical, medical device, and drug delivery systems. 